Exploring the recent advancements and future prospects of personalized medicine in type 2 diabetes

The pathophysiology of Type 2 Diabetes (T2D) is intricate, involving three main processes that lead to elevated glucose levels. Insulin resistance hinders glucose utilization in muscles, adipose tissue, and the liver. Additionally, pancreatic dysfunction results in excessive glucose release and disrupts insulin and glucagon levels, contributing to hyperglycemia. Tailoring management strategies to individual needs and stages of the disease is crucial. Genetic factors play a significant role in the development of T2D and must be considered in treatment planning. Genome-Wide Association Studies (GWAS) have identified numerous genetic loci and Single Nucleotide Polymorphisms (SNPs) associated with T2D. A personalized approach considers a wide range of factors, such as patient characteristics, medical history, complications, and genetic makeup. By customizing treatment plans to suit each patient's unique needs, it may be possible to improve outcomes and reduce the impact of T2D on overall health. While some may argue that personalized diabetes care has been utilized for a long time, integrating it into the standard treatment of T2D remains a challenging task with numerous obstacles.

The current review aims to describe the vision of personalized medicine in diabetes and offers helpful suggestions for a better understanding of this issue, as well as disseminating information about novel treatment approaches like Next Generation Sequencing (NGS) and pharmacotherapy.